Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

RESEARCH

PsoProtect International Registry

PsoProtect is an international registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. The registry seeks to improve our understanding of how factors such as immunomodulator therapies and comorbidities impact outcomes to COVID-19 in psoriasis. This information will inform clinicians when assessing risk and treating COVID-19 in patients with psoriasis. 

 

RELEVANT PUBLICATIONS

The Virologic and Immunologic Effects of Cyclosporine as an Adjunct to Antiretroviral Therapy in Patients Treated during Acute and Early HIV-1 Infection | Martin Markowitz, Florin Vaida, C. Bradley Hare, Daniel Boden, Hiroshi Mohri, Frederick M. Hecht, Robert C. Kalayjian, Ann Conrad, Donna Mildvan, Judith Aberg, Christine Hogan, J. Michael Kilby, Henry H. Balfour, Jr, Kim Schafer, Douglas Richman, Susan Little

COVID-19: risk for cytokine targeting in chronic inflammatory diseases? | Georg Schett, Michael Sticherling and Markus F. Neurath

Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears | Megna M, Ruggiero A, Marasca C, Fabbrocini G

Journal articles on coronavirus with relevance for skin diseases and dermatology | Centre of Evidence Based Dermatology (CEBD) Coronavirus Resource for Dermatology

Cutaneous manifestations in COVID‐19: a first perspective | S. Recalcati

Skin manifestations are emerging in the coronavirus pandemic | M. Alexander Otto

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease | Richardson P, Griffin I, Tucker C, Smith D, Oechsie O, Phelan A, Stebbing J

COVID-19: combining antiviral and anti-inflammatory treatments | Stebbing J, Phelan A, Griffin I, Tucker C, Oechsie O, Smith D, Richardson P

Baricitinib for COVID-19: a suitable treatment? | Favalli EG, Biggioggero M, Maioli G, Caporali R

Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients | Barrett L

Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. (BARI-COVID) | Cantini F

Psoriasis health care in the time of the coronavirus pandemic: insights from dedicated centers in sardinia (Italy) | Atzori L, Mugheddu C, Addis G, Sanna S, Satta R, Ferreli C, Atzori MG, Montesu MA, Rongioletti F.

SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor | Messina F, Piaserico S.

Psoriasis and Psoriatic Arthritis: how to manage Immunosuppressants in COVID-19 days | Coletto LA, Favalli EG, Caporali R.

Biologics for psoriasis during COVID-19 outbreak | Murrell DF, Rivera-Oyola R, Lebwohl M.

Biologics for psoriasis during COVID-19 outbreak | Di Lernia V.

Reply to "COVID-19, syphilis and biologic therapies for psoriasis and psoriatic arthritis: A word of caution" | Lebwohl M, Rivera-Oyola R, Murrell DF.

Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic | Torres T, Puig L.

SECURE-Psoriasis: A de-identified registry of psoriasis patients diagnosed with COVID-19 | Balogh EA, Heron C, Feldman SR, Huang WW.

A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic? | Kutlu Ö, Metin A.

Biologic therapy for psoriasis during the covid-19 outbreak is not a choice. | Bardazzi F, Loi C, Sacchelli L, Di Altobrando A.

One more paper towel, longer protection. | Yu N, Wu L, Su J, Huang K, Zhao S, Chen X.

COVID-19, syphilis and biologic therapies for psoriasis and psoriatic arthritis: A word of caution. | Kansal NK.

Comment on "COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action". | Abdelmaksoud A, Goldust M, Vestita M.

Should biologics for psoriasis be interrupted in the era of COVID-19? | Lebwohl M, Rivera-Oyola R, Murrell DF.

COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action. | Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I.

COVID-19 and Immunomodulator / Immunosuppressant Use in Dermatology. | Price KN, Frew JW, Hsiao JL, Shi VY.


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK